SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of TCR2 Therapeutics Inc. (TCRR)

Newsfile 23-Mar-2023 10:58 AM

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - March 23, 2023) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of TCR² Therapeutics Inc. ("TCR²" or the "Company") (NASDAQ:TCRR) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company's agreement to merge with Adaptimmune Therapeutics plc. ("Adaptimmune") (NASDAQ:ADAP). Under the terms of the all-stock agreement, TCR² stockholders will receive 1.5117 Adaptimmune ADS for each TCR² share. Following the closing of the transaction, Adaptimmune shareholders will own approximately 75% of the combined company and TCR² stockholders will own approximately 25% of the combined company.

The investigation concerns whether the TCR² Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to TCR² shareholders in the combined company.

If you own shares of TCR² stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, visit https://www.brodskysmith.com/cases/tcr%c2%b2-therapeutics-inc-nasdaq-tcrr/, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/159591